2.15

3.86% 0.08

Gain Therapeutics Inc (GANX)

Overview News Price History Option Chain Financials Why GANX Down? Discussions Forecast

Gain Therapeutics Inc stock is traded at $2.15, with a volume of 156.30K. It is up +3.86% in the last 24 hours and up +18.13% over the past month. Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Previous Close:

$2.07

Open:

$2.06

24h Volume:

156.30K

Relative Volume:

0.39

Market Cap:

$52.86M

Revenue:

$210.70K

Net Income/Loss:

$-22.22M

P/E Ratio:

-1.1813

EPS:

-1.82

Net Cash Flow:

$-17.13M

1W Performance:

-16.34%

1M Performance:

+18.13%

6M Performance:

-27.36%

1Y Performance:

-25.09%

1-Day Range:

$2.0201

$2.30

1-Week Range:

$2.0201

$2.58

52-Week Range:

$0.89

$5.33

Gain Therapeutics Inc Stock (GANX) Company Profile

Name

Gain Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(301) 500-1556

Address

4800 HAMPDEN LANE, BETHESDA

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

GANX's Discussions on Twitter

Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-12-21	Initiated	BTIG Research	Buy
Apr-12-21	Initiated	Oppenheimer	Outperform

Gain Therapeutics Inc Stock (GANX) Latest News

Nov 01, 2024

2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money

Nov 01, 2024

Hoping for a weight-loss pill? It could get closer to reality next week. - MarketWatch

Nov 01, 2024

individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance

Nov 01, 2024

Oct 31, 2024

Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211% - Yahoo Finance

Oct 31, 2024

Oct 29, 2024

Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 12.6% - MarketBeat

Oct 29, 2024

Oct 28, 2024

Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance

Oct 28, 2024

Nuclear stocks gain on AI optimism: Oklo, NuScale, Centrus - Yahoo Finance

Oct 28, 2024

Oct 24, 2024

Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain - Yahoo Finance

Oct 24, 2024

Oct 23, 2024

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 - The Manila Times

Oct 23, 2024

What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St

Oct 23, 2024

Oct 21, 2024

Gain Therapeutics Regains Nasdaq Compliance - Investing.com

Oct 21, 2024

Gain Therapeutics Regains Nasdaq Compliance By Investing.com - Investing.com UK

Oct 21, 2024

Oct 18, 2024

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - MSN

Oct 18, 2024

32 NMEs gain US FDA clearance through Q3, approvals up over 2023 - BioWorld Online

Oct 18, 2024

Oct 16, 2024

Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN

Oct 16, 2024

How should investors view Janux Therapeutics Inc (JANX)? - US Post News

Oct 16, 2024

What was Gain Therapeutics Inc (GANX)’s performance in the last session? - US Post News

Oct 16, 2024

Oct 15, 2024